跳至主要内容
临床试验/NCT05201625
NCT05201625Unknown不适用

Markers of Severity in Covid 19 Patients

Sohag University1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2021年12月15日最近更新:
适应症

试验速览

阶段
不适用
入组人数
90
试验地点
1
主要终点
Markers of severity(S100A8&S100A12) in Sever respiratory syndrome coronavirus 2 (SARS-COV-2) patients

研究概览

简要总结

Patients infected with covid-19 have a series of clinical manifestations, including fever, cough, myalgia or fatigue, dyspnea, even acute respiratory distress syndrome (ARDS), acute cardiac injury and secondary infection, and a lot of sever patients had to been admitted to the intensive care unit (ICU)

One of the hallmark of COVID 19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. besides the positive viral nucleic acid analysis and the representative pulmonary CT findings (bilateral distribution of patchy shadows and ground glass opacity), most individual patients showed the changes in several immunological and biological markers . CD177 which is one of the most clinically important neutrophil alloantigen because: i) it is a neutrophil-specific marker representative of neutrophil activation, ii) it was the most highly differentiated expressed gene in patients, and iii) the protein can be measured in the serum, making its use as a marker clinically applicable. It is expressed on neutrophils, neutrophilic metamyelocytes, and myelocytes . Given the contribution of the neutrophil activation pathway in the clustering of COVID-19 patients, neutrophil-activation features that could act as possible reliable markers of disease evolution.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • COVID 19 hospitalized patients (diagnosed by RT-PCR)

排除标准

  • Age below 18 years and above 80.

结局指标

主要结局

Markers of severity(S100A8&S100A12) in Sever respiratory syndrome coronavirus 2 (SARS-COV-2) patients

时间窗: one year

Measuring level of S100A8 and S100A12 by ELISA.

Markers of severity(CD177) in Sever respiratory syndrome coronavirus 2 (SARS-COV-2) patients

时间窗: one year

- Measuring gene expression for CD 177 by RT-PCR and also by ELISA. Measuring gene expression for CD 177 by RT-PCR and also by ELISA.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mai Hamdy Hamed

Assistant lecturer of microbiology and immunology in sohag general hospital

Sohag University

研究点 (1)

Loading locations...

相似试验

Markers of Severity (CD177,S100A8 &S100A12) in Sever... | 临床试验